Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)
IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral
